7.96BMarket Cap-9680P/E (TTM)
8.410High8.150Low6.44MVolume8.380Open8.340Pre Close52.98MTurnover0.67%Turnover RatioLossP/E (Static)971.49MShares21.35052wk High26.42P/B7.90BFloat Cap6.03052wk Low--Dividend TTM964.89MShs Float73.450Historical High--Dividend LFY3.12%Amplitude6.030Historical Low8.222Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
MEDBOT-B Stock Forum
Finally on, but did not hit a new subscription. The market is not friendly to unprofitable start-ups, and expect a more comfortable price. Kingsley bio and minimally invasive robotics are the most focused directions for innovative drugs and innovative medical devices in the future. It is nothing more than the time and rhythm of the completion of the warehouse.
The big Four are 10 years ahead of their time in technology, waiting for the world to catch up, and they have their own medical robots. Da Vinci launched its products in 2000 based on the underlying technology of the robot industry. The more cases there are, the more powerful they are.
Several key points, not profitable, High ling IPO increase, JPMORGAN Chase sponsor, expected 50% callback, IPO for the previous investment rise range is still ok, speculation new mood has not recovered;
In summary, in terms of playing new, the probability of winning is almost 50/50, the odds are not high, if the call back to break the resistance to save slightly bigger
No comment yet